Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

Press Releases
Typography

NANOBIOTIX , a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma.

The last patients are expected to start their treatment in two to three weeks.Elsa Borghi, Nanobiotix's Chief Medical Officer commented: "We are pleased to have reached this important milestone in Nanobiotix's soft tissue sarcoma study, and we look forward to reporting our first data next year."

The pivotal international Phase II/III study in soft tissue sarcoma was launched in Europe and Asia in October 2014 and aims to evaluate the safety and the efficacy of NBTXR3, a first-in-class radio-enhancer that could potentially target most solid tumors. The Phase II/III study is a prospective, randomized, multi-center, open label and active controlled two-arm study of 156 patients with locally advanced soft tissue sarcoma.

The trial's primary endpoint is the complete pathological response rate. The secondary endpoints are the objective response rate (ORR) by imaging (MRI); the evaluation of the safety profile in terms of clinical and laboratory adverse events; the tumor volume changes; the resection margins and the limb amputation rate. Furthermore, an exploratory analysis of the progression free survival is planned once the follow-up period has been completed for all treated patients.

Nanobiotix expects to present the results of its Phase II/III trial in soft tissue sarcoma in the first half of 2018.

For more information about the study: Clinical trial.gov and http://www.actinsarc.com/

About NANOBIOTIX:www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

In 2016 the Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company's Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

Contact

Nanobiotix
Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.

Noel Kurdi
Director, Investor Relations
+1 (646) 241-4400
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.

Media relations
France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
This email address is being protected from spambots. You need JavaScript enabled to view it.

United States - RooneyPartners
Marion Janic
+1 (212) 223-4017
This email address is being protected from spambots. You need JavaScript enabled to view it.